Shareholders Have Faith in Loss-making Madrigal Pharmaceuticals (NASDAQ:MDGL) as Stock Climbs 55% in Past Week, Taking Three-year Gain to 267%
Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences
Madrigal Pharmaceuticals Insider Sold Shares Worth $1,504,703, According to a Recent SEC Filing
Madrigal Pharmaceuticals Is Maintained at Neutral by B. Riley Securities
Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Travere Therapeutics (TVTX) and Regeneron (REGN)
Express News | Madrigal Pharmaceuticals Inc : B. Riley Raises Target Price to $236 From $194